Evaluation of Mucosamin Effect on Treating Radiation Induced Oral Mucositis during and after Radiotherapy amongst Patients with Oral Cavity Squamous Cell Carcinoma.

Hamid Nasrollahi,Behnam Kadkhodaei,Nezhat Khanjani,Shapoor Omidvari,Saeedeh Khaki,Sayed Hasan Hamedi,Ahmad Mosalaei,Mansour Ansari,Mohammad Mohammadianpanah,Niloofar Ahmadloo

doi:10.31557/apjcp.2021.22.11.3711

Abstract

Background:Oral mucositis is a serious complication radiation therapy for cancer. This is a major complication during radiation therapy of the head and neck tumors in approximately all patients. Therefore, this study was conducted to evaluate the effect of Mucosamin on treatment of radiation induced oral mucositis during and after radiotherapy amongst patients with oral cavity squamous cell carcinoma. Materials and Methods:In this prospective clinical trial, eligible patients who referred to radiation oncology department of Namazi Hospital, Shiraz, Iran from Jan 2018 till Jan 2019 were evaluated. The cases with confirmed pathologic diagnosis of squamous cell carcinoma of the oral cavity underwent 6,000 cGy radiation therapy and were randomly divided into two groups: 1- Intervention group; Mucosamin spray for 3-4 times a day (n = 40); 2 - Control group; standard medications (3 times a day) (n = 40). Oral mucositis was evaluated weekly based on RTOG scoring scale. Grade of mucositis was recorded during treatment and after radiation therapy. Results:A total of 80 patients were divided in two groups of Mucosamin and control. From week 3 until the end of radiotherapy (week 6) and after radiotherapy (week 8), there was a significant difference in the severity of oral mucositis between the Mucosamin and the control groups (P <0.05). Conclusion:The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma.

Highlights

Oral cavity cancers account for 2-4 percent of all human cancers
A total of 80 patients with Oral squamous cell carcinoma (OSCC) were evaluated for the effects of mucosamin on radiation-induced oral mucositis in the intervention and control groups
Patients diagnosed with squamous cell carcinoma of the oral cavity received 60 Gy radiotherapy over a period of 6 weeks, some received chemotherapy or target therapy

Summary

Introduction

Oral cavity cancers account for 2-4 percent of all human cancers. In some areas of the world, the incidence of oral cancer is higher; for example, in India and Pakistan, 45% and 10% of all cancers are Oral squamous cell carcinoma (OSCC) (Sharma et al, 2010). Radiation therapy (RT) is an important part of OSCC treatment (Kwong, 2004) ; oral mucositis is a serious complication during radiotherapy. This is a major complication during radiation therapy for head and neck tumors that occurs in all of the patients. This study was conducted to evaluate the effect of Mucosamin on treatment of radiation induced oral mucositis during and after radiotherapy amongst patients with oral cavity squamous cell carcinoma. Conclusion: The results of this study showed that Mucosamin spray was able to significantly improved radiation-induced oral mucositis in patients with oral squamous cell carcinoma

Methods

Results

Conclusion